Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Matthew Smith

Neurocritical Care Cincinnati, OH Medical Doctor

NPI 1861879686 CMS profile 4227386

3188 Bellevue Ave, Cincinnati, OH 45219

Open in the dashboard

General payments

$2,168

17 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Matthew Smith of Cincinnati, OH is reported in the CMS Open Payments database as having received $2,168 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Neurocritical Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $556 2
2023 General $380 5
2022 General $826 3
2021 General $227 3
2020 General $93 3
2019 General $87 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Smith
  • Neurocritical Care median
  • Middle half of Neurocritical Care
  • National median

In program year 2025, general payments to Matthew Smith were reported at $0. Among 223 Neurocritical Care profiles paid that year, the median was $98 and the middle half received between $34 and $262.

Show as a table
Year Matthew Smith Neurocritical Care median Middle half National median
2019 $87 $125 $47–$286 $163
2020 $93 $74 $21–$153 $114
2021 $227 $108 $34–$250 $132
2022 $826 $115 $31–$277 $149
2023 $380 $127 $35–$275 $160
2024 $556 $127 $44–$265 $164
2025 $0 $98 $34–$262 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. MicroVention, Inc. $944 2 payments
  2. Becton, Dickinson and Company $406 1 payment
  3. Medtronic, Inc. $163 2 payments
  4. Penumbra, Inc. $146 1 payment
  5. Alexion Pharmaceuticals, Inc. $117 1 payment
  6. Lilly USA, LLC $93 3 payments
  7. Biogen, Inc. $87 1 payment
  8. Stryker Corporation $78 2 payments
  9. Medical Device Business Services, Inc. $64 1 payment
  10. Scientia Vascular $33 1 payment
  11. Other $37 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $969 15 payments
  2. Travel and Lodging $793 1 payment
  3. Consulting Fee $406 1 payment
Products named General payments · program years 2019–2024
  1. WEB ANEURYSM EMBOLIZATION SYSTEM $150 1 payment
  2. SOFIA 6F-131CM STR $150 1 payment
  3. ERIC RETRIEVAL DEVICE $150 1 payment
  4. LVIS JUNIOR $150 1 payment
  5. RED 72 $146 1 payment
  6. SOLITAIRE X $146 1 payment
  7. Andexxa $117 1 payment
  8. TYSABRI $87 1 payment
  9. TRUFILL $64 1 payment
  10. SURPASS EVOLVE $46 1 payment
  11. Other $87 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

35

Median for Neurology: 833

Drug cost

$313

Median for Neurology: $202,670

Branded share of claims

60%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levetiracetam Generic 14 $179
Clopidogrel Clopidogrel Bisulfate Brand 21 $134

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$64,190

Medicare's payments for the services billed

Medicare patients

141

Average age 71

Services billed

416

64 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 54%
Chronic kidney disease 43%
Diabetes 41%
Atrial fibrillation 40%
Heart failure 35%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurocritical Care in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record